Skip to content
Review Open access

Mechanisms of cetuximab resistance in head and neck squamous cell Carcinoma: Focus on the EGFR-ERK pathway.

Oct 2026 · Biochemical Pharmacology · Vol 254, pp. 118568 · 0 citations · 406 references
Medicine

TL;DR

Combined targeting of ERK and EGFR may represent a promising strategy for overcoming cetuximab resistance in selected molecular contexts.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Major risk factors include tobacco use, excessive alcohol consumption, and infection with oncogenic human papillomaviruses (HPV). Despite advances in treatment, HNSCC remains associated with poor outcomes, particularly in patients with advanced or recurrent/metastatic disease. The epidermal growth factor receptor (EGFR) has been recognized as a key oncogenic driver in HNSCC, as it is frequently overexpressed and promotes activation of multiple pro-tumorigenic signaling pathways, including ERK and PI3K/Akt. Cetuximab remains the only approved molecularly targeted agent directed against a tumor-associated receptor in HNSCC. However, its clinical benefit is limited by low response rates and the frequent development of resistance even in initially responsive tumors. Understanding the molecular basis of resistance to EGFR-targeted therapy is therefore critical for developing more effective pharmacological strategies and improving the clinical utility of cetuximab. In this review, we summarize EGFR alterations, activation of parallel compensatory pathways, and the reactivation of downstream signaling cascades, including PI3K/Akt and Ras/ERK, as major mechanisms underlying resistance to EGFR-targeted therapy in HNSCC. We focus particularly on the ERK signaling pathway as a central integrator of genetic, epigenetic, and adaptive resistance mechanisms. Sustained ERK activity restores downstream EGFR outputs, promotes feedback ligand production, drives epithelial-mesenchymal transition and cellular plasticity, and engages parallel oncogenic pathways, thereby enabling tumor cells to evade cetuximab-mediated EGFR blockade. Combined targeting of ERK and EGFR may therefore represent a promising strategy for overcoming cetuximab resistance in selected molecular contexts.

Read PDF

Similar papers

Review Open access 2026

Advancing Precision Oncology in the USA: A Literature Review of EGFR, MYC, and RAS Alterations in Head and Neck Cancers

Head and neck cancers (HNCs) constitute a diverse group of malignancies characterized by complex molecular alterations that contribute to tumor initiation, progression, therapeutic resistance, and clinical heterogeneity. In the era of precision oncology in the United States, a comprehensive understanding of key oncogen...

Yinemili Castro Oropeza, Ameera Qaddo, Dosapati Komala Preethi et al. · 0 citations
Review Oct 2026

A Comprehensive Review of Triple-Negative Breast Cancer and Recent Advances in Acridone Derivatives for Its Treatment

Acridone derivatives constitute a very promising scaffold for the design of therapeutics targeting EGFR in the treatment of TNBC, and further structural modifications are necessary to improve potency, selectivity, and pharmacokinetics for EGFR-based TNBC agents.

Abhishek Kumar, Kamal Shah · 0 citations
Case report Open access Sep 2026

Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report

A case of a patient with advanced HCC who developed cutaneous, pulmonary, and lymphatic metastases following failure of multiple lines of tyrosine kinase inhibitors including donafenib and regorafenib is presented, highlighting the potential benefit of an EGFR-targeted triplet strategy in refractory HCC with EGFR prote...

Qin Xu, Xiao-Fen Li, Rui Zhu et al. · 0 citations
Oct 2026

Abstract C119: Characterizing FOXC1 dysregulation in triple-negative breast cancer to advance precision therapies and reduce cancer health disparities

Breast cancer is the most common cancer in women and the second leading cause of cancer death in the United States. Breast cancer has multiple subtypes defined by the expression of the estrogen receptor (ESR1), progesterone receptor (PGR), and human epidermal growth factor receptor 2 (HER2). Among breast cancer subty...

Chung S. Lee, Huan Cao, Vannah Algador et al. · 0 citations
Review Open access Sep 2026

From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.

The role of EGFRvIII in driving aggressive tumor growth is discussed and how effective targeting of EGFRvIII, and overcoming resistance mutations will be crucial to improve EGFR- and EGFRvIII-based therapies are highlighted.

U. Krishnaja, N. J, Maitheli Sarkar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.